Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

NCT01234649 on ClinicalTrials.gov · last registry update 2019-07-26

A small phase 3 — 153 participants, against a typical 424. The sponsor logged completion for 24 April 2019. Primary outcome, as filed: Insulin Secretion-Sensitivity Index (IS-SI). liraglutide is approved in the US, but not for diabetes and metabolic syndrome — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Woman's
Sponsor type: Other
Enrollment: 153
Started: 2011-08-11
Primary completion: 2019-04-24 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Insulin Secretion-Sensitivity Index (IS-SI)

Conditions studied

Gestational Diabetes Mellitus · Type 2 Diabetes Mellitus · Metabolic Syndrome · Impaired Glucose Tolerance · Disorder of Glucose Regulation

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.